Search News ArchivesExhibitions & EventsWill BRIC be the Savior for the Life Sciences and Medical Devices Sector? BioCity to develop BioHub at Alderley Park Willetts’ announcement underpins need for accountability in research Seal of Approval for Pepceuticals New Pipet-X™ Pipette Controller – Reliable, Easy & Comfortable to Use IDT and SGI-DNA Broaden Their Collaboration to Provide Synthetic DNA Products up to 2 Mbp New Portable SPECTROSCOUT XRF Analyzer - the Lab that Goes Anywhere Novel RNA detection reagent enables gene expression analysis in living cells
Not happy with your ion chromatograph? Switch to Metrohm now and save! Debunking Myths about Peak Area Response of Glycoprotein Oligosaccharides Thermo Fisher Scientific Introduces Next Generation Ion Chromatography Suppressor ACE SuperC18 Ultra-Inert Extended pH Stability UHPLC and HPLC Columns Solid Phase Microextraction (SPME) Specialty Vials and Seals Merck Millipore to Highlight Capabilities in LC-MS at ASMS Revolutionize your pipetting with the new Biohit Picus electronic pipette Easy, Reliable Weighing in Regulated Areas Phenom proX all-in-one desktop SEM Flash of inspiration in the shaft tunnel - IKA launches the new video for UTTD control The only Chromatography Autosampler you will ever need! JG Finneran Associates introduces the 96-Well Multi-Tier Microtiter Plate System (Patented) IC for the people – Metrohm celebrates 25 years of ion chromatography
For further information or to sign up to receive any of our E-Newsletters click here Hitachi launches 3rd generation Tabletop Microscope BioTek releases Cytation™3 Cell Imaging Multi-Mode Reader Easy to use imaging and analysis with cellSens 1.8 Bruker and SCiLS GmbH Announce an Exclusive Partnership for SCiLS Lab Software for MALDI Imaging Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology Qualoupe LIMS from Two Fold Software helps contract testing laboratories grow and develop business Ocean Optics Launches Powerful New Spectroscopy Software Thermo Fisher Scientific launches intuitive online tool for automation platform configuration Boehringer Ingelheim Implements Titian’s Mosaic Software to Manage New Biological Entity Samples Waters Biopharmaceutical, Bioanalysis and Screening Solutions Now Shipping with UNIFI 1.6 Molecular Devices Introduces SoftMax Pro 6 GxP Microplate Data Acquisition and Analysis Software |
The Institute of Cancer Research names Professor Alan Ashworth FRS as new CEOEurope's leading cancer research centre, The Institute of Cancer Research (ICR), has named eminent scientist Professor Alan Ashworth as its new Chief Executive. Professor Ashworth will take up the appointment in January. Professor Ashworth, who joined the ICR in 1986, is a world leader in cancer research and has been Director of the Breakthrough Breast Cancer Research Centre at the ICR since 1999. One of Professor Ashworth's major contributions to cancer research has been his work on genes involved in cancer risk. He was a key part of the team that in 1995 discovered the gene BRCA2, which is linked to an increased risk of some types of cancers. Ten years later, Professor Ashworth identified a way to exploit genetic weaknesses in cancer cells including mutated BRCA2 to create a new type of personalised medicine. As well as developing new drugs, he is also is joint leader of the world's most comprehensive study into the causes of breast cancer, the Breakthrough Generations Study, which is monitoring 100,000 women over 40 years. A Professor of Molecular Biology and a Fellow of the Royal Society, his present focus is translating laboratory studies into an improvement in patient care. "I am honoured and thrilled to be selected to lead such a respected organisation with a proud 100-year history of achievement in cancer research," Professor Ashworth says. "As we move into an era of targeting treatments at the specific causes of a patient's cancer, the ICR's partnership with The Royal Marsden will put it in a unique position to ensure our new research benefits patients as quickly as possible. I am very excited by the opportunity to build on the ICR's considerable successes in improving the lives of people with cancer." Professor Ashworth will replace outgoing Chief Executive Professor Peter Rigby, who will step down in January 2011. Under Professor Rigby the ICR acheived the number one ranking among the UK's 132 higher education research centres in the authoritative analysis of the most recent Higher Education Funding Council's Research Assessment Exercise. Lord Ryder, Chairman of the ICR, says: "Professor Peter Rigby's leadership of the ICR over the past 11 years has been outstanding. His drive and inspiration have turned the ICR into a global centre of excellence. We all owe him a huge debt of gratitude. "Professor Ashworth is Professor Rigby's natural successor. His work at the ICR has been admired and respected; he is a scientist of world renown who has shown superb leadership qualities as Director of the Breakthrough Breast Cancer Research Centre. He takes over as chief executive with the full support and good wishes of the staff and board of the ICR." The Institute of Cancer Research (ICR)
For more information visit www.icr.ac.uk |
June American Society for Mass Spectroscopy - Annual Conference (ASMS) 14th Annual Drug Discovery Leaders Summit 2013 Discovery Chemistry & Drug Design Congress 2013 5th Annual Drug Development Congress 2013 Single Cell Genomics & Transcriptomics Asia Congress 2013 Next Generation Sequencing Data Congress 2013 Malvern Instruments announces global agreement with Proveris Scientific Astronomy Researchers Relocate to Liverpool Science Park Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility at Billingham, UK Site Malvern Instruments wins decisive victory over Wyatt Technology Corporation in US Court of Appeals |